Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction

Background This retrospective, multicenter study aimed to reveal risk predictors for mortality in the intensive care unit (ICU) as well as survival after ICU discharge in patients with acute myeloid leukemia (AML) requiring treatment in the ICU. Methods and Results Multivariate analysis of data for 187 adults with AML treated in the ICU in one institution revealed the following as independent prognostic factors for death in the ICU: arterial oxygen partial pressure below 72 mmHg, active AML and systemic inflammatory response syndrome upon ICU admission, and need for hemodialysis and mechanical ventilation in the ICU. Based on these variables, we developed an ICU mortality score and validated the score in an independent cohort of 264 patients treated in the ICU in three additional tertiary hospitals. Compared with the Simplified Acute Physiology Score (SAPS) II, the Logistic Organ Dysfunction (LOD) score, and the Sequential Organ Failure Assessment (SOFA) score, our score yielded a better prediction of ICU mortality in the receiver operator characteristics (ROC) analysis (AUC = 0.913 vs. AUC = 0.710 [SAPS II], AUC = 0.708 [LOD], and 0.770 [SOFA] in the training cohort; AUC = 0.841 for the developed score vs. AUC = 0.730 [SAPSII], AUC = 0.773 [LOD], and 0.783 [SOFA] in the validation cohort). Factors predicting decreased survival after ICU discharge were as follows: relapse or refractory disease, previous allogeneic stem cell transplantation, time between hospital admission and ICU admission, time spent in ICU, impaired diuresis, Glasgow Coma Scale <8 and hematocrit of ≥25% at ICU admission. Based on these factors, an ICU survival score was created and used for risk stratification into three risk groups. This stratification discriminated distinct survival rates after ICU discharge. Conclusions Our data emphasize that although individual risks differ widely depending on the patient and disease status, a substantial portion of critically ill patients with AML benefit from intensive care.

[1]  E. Estey,et al.  Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Chevret,et al.  Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium--a groupe de recherche respiratoire en réanimation onco-hématologique study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Cayuela,et al.  Red blood cell transfusion in non-bleeding critically ill patients with moderate anemia: is there a benefit? , 2013, Intensive Care Medicine.

[4]  Á. HeRReRa-gómez,et al.  Outcome of critically ill patients with hematological malignancies , 2013, Annals of Hematology.

[5]  Jin Woo Kim,et al.  Prognostic factors in critically ill patients with hematologic malignancies admitted to the intensive care unit. , 2012, Journal of critical care.

[6]  K. Klein,et al.  Outcomes and prognostic factors for patients with acute myeloid leukemia admitted to the intensive care unit , 2012, Leukemia & lymphoma.

[7]  F. Farassati,et al.  Effect of sequential docetaxel followed by mTOR inhibitor temsirolimus on suppression of PI3K overactivation resistance mechanism. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  W. Hiddemann,et al.  Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  W. Hiddemann,et al.  Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. , 2012, The Lancet. Oncology.

[10]  U. Dührsen,et al.  Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  M. Potter,et al.  Outcomes and prognostic factors in patients with haematological malignancy admitted to a specialist cancer intensive care unit: a 5 yr study. , 2012, British journal of anaesthesia.

[12]  H. Dombret,et al.  Intensive care unit management of patients with newly diagnosed acute myeloid leukemia with no organ failure , 2012, Leukemia & lymphoma.

[13]  É. Azoulay,et al.  Survival in neutropenic patients with severe sepsis or septic shock* , 2012, Critical care medicine.

[14]  W. Hiddemann,et al.  Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial , 2011, Haematologica.

[15]  S. Pinto‐Sietsma,et al.  Prognosis of patients with haematological malignancies admitted to the intensive care unit: Sequential Organ Failure Assessment (SOFA) trend is a powerful predictor of mortality. , 2011, European journal of internal medicine.

[16]  K. Laczika,et al.  Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience , 2011, Haematologica.

[17]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[18]  W. Hiddemann,et al.  Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes , 2010, The Lancet.

[19]  M. Gilbert,et al.  Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Bagshaw,et al.  Clinical characteristics and outcomes of patients with acute myelogenous leukemia admitted to intensive care: a case-control study , 2010, BMC Cancer.

[21]  H. Gundacker,et al.  Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[23]  D. Harrison,et al.  Admission factors associated with hospital mortality in patients with haematological malignancy admitted to UK adult, general critical care units: a secondary analysis of the ICNARC Case Mix Programme Database , 2009, Critical care.

[24]  W. Hiddemann,et al.  Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. , 2009, Blood.

[25]  Jo-Anne H. Young Infectious complications of acute and chronic GVHD. , 2008, Best practice & research. Clinical haematology.

[26]  M. Carvalho,et al.  Prognosis of critically ill patients with cancer and acute renal dysfunction. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  W. Hiddemann,et al.  Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. , 2006, Blood.

[28]  M. Wujtewicz,et al.  Patients with haematological malignancies requiring invasive mechanical ventilation: differences between survivors and non-survivors in intensive care unit , 2005, Supportive Care in Cancer.

[29]  M. Paesmans,et al.  Scoring systems in cancer patients admitted for an acute complication in a medical intensive care unit , 2000, Critical care medicine.

[30]  G. Wells,et al.  A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. , 1999, The New England journal of medicine.

[31]  C. Sprung,et al.  Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. , 1998, Critical care medicine.

[32]  Corinne Alberti,et al.  The Logistic Organ Dysfunction system. A new way to assess organ dysfunction in the intensive care unit. ICU Scoring Group. , 1996, JAMA.

[33]  J. Vincent,et al.  The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure , 1996, Intensive Care Medicine.

[34]  J. L. Gall,et al.  APACHE II--a severity of disease classification system. , 1986, Critical care medicine.

[35]  E. Draper,et al.  APACHE II: A severity of disease classification system , 1985, Critical care medicine.

[36]  W. Knaus,et al.  APACHE II: a severity of disease classification system. , 1985 .

[37]  R. Rimel,et al.  THE GLASGOW COMA SCALE: TO SUM OR NOT TO SUM? , 1983, The Lancet.

[38]  L. Weintraub,et al.  Leukocyte larceny: a cause of spurious hypoxemia. , 1979, The American journal of medicine.

[39]  Susan M. Chang,et al.  Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  S. Lemeshow,et al.  A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. , 1993, JAMA.